The Effect of Vitamin C Supplementation on Gut Microbiota Composition and Function in Healthy Adults

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Glasgow

About this trial

The aim of this dietary intervention study is to explore how vitamin C affects the bacteria that live in our gut. Vitamins are essential nutrients found in fruits and vegetables. Our bodies cannot make them on their own, but we need them to function correctly. Vitamins play various roles, including supporting the immune system and assisting with energy production. Some vitamins in our diet can reach the large intestine, where they may be used by gut bacteria to promote their growth. In this study, we aim to investigate how our gut bacteria interact with vitamin C and how this interaction affects their growth and activity.

For this study, participants will follow their habitual diet for one-week (run-in period), followed by two consecutive two-week supplementation periods in which they will first take a moderate dose (200 mg/day) and then a high-dose (1000 mg/day) of vitamin C. A final one-week period follow up period will involve a return to their habitual diet. Faecal, blood and urine samples will be collected at the start and end of each supplementation period to explore changes in gut microbiota composition, activity and markers of inflammation.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Healthy individuals aged 18-65 years with a BMI between 18.5-35 Kg/m2

Self-reported good health with no chronic conditions requiring regular medical care

Willing to provide blood, urine, and stool samples at multiple time points

Disqualifiers

Aged <18 or >65 years

Smoking

Chronic illness requiring regular medication or GP visits

Current or recent medication affecting gut transit or digestion

Trial design

Design model

Sequential

Treatments tested in this trial

  • Moderate Vitamin C dose (200 mg)

    Dietary supplement

    200 mg of vitamin C provided as a chewable tablet, taken orally daily for two weeks

  • High-dose vitamin C supplementation (1000 mg)

    Dietary supplement

    1000 mg of Vitamin C provided as a chewable tablet, taken orally daily for two weeks

  • Habitual diet (run in period)

    Other intervention

    this is a run-in period where participants consume their habitual diet for one week

Treatment groups

23 Participants
are divided into 1 treatment group
Group A: Sequential vitamin C interventionExperimental treatment 3 interventions

Trial outcomes

Primary outcomes

1

Butyrate (Short Chain Fatty Acid)

Quantified in stool samples using Gas Chromatography

Time frame
Baseline (Visit 1), Week 1 (Visit 2), Week 3 (Visit 3), Week 5 (Visit 4) and Week 6 (Visit 5)
2

Short Chain Fatty Acids i.e. acetate, propionate, butyrate, total

Quantified in stool samples using Gas Chromatography

Time frame
Baseline (Visit 1), Week 1 (Visit 2), Week 3 (Visit 3), Week 5 (Visit 4) and Week 6 (Visit 5)
3

Stool microbiota composition analysis

16S rRNA gene amplicon sequencing from faecal DNA extracts

Time frame
Baseline (Visit 1), Week 1 (Visit 2), Week 3 (Visit 3), Week 5 (Visit 4) and Week 6 (Visit 5)

Secondary outcomes

1

Stool pH

pH meter

Time frame
Baseline (Visit 1), Week 1 (Visit 2), Week 3 (Visit 3), Week 5 (Visit 4) and Week 6 (Visit 5)
2

Vitamin C in plasma

Using validated analytical techniques

Time frame
Week 1 (Visit 2), Week 3 (Visit 3), and Week 5 (Visit 4)
3

Inflammatory markers

Using Elisa or multiplex assays

Time frame
Week 1 (Visit 2), Week 3 (Visit 3), and Week 5 (Visit 4)

Other outcomes

1

Gut barrier function markers

Quantified in plasma using standard enzyme-linked immunosorbent assay.

Time frame
Week 1 (Visit 2), Week 3 (Visit 3), and Week 5 (Visit 4)

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Glasgow

Lead sponsor

Professor Konstantinos Gerasimidis, University of Glasgow

Collaborator